FDA Approved: CABLIVI — Supplemental Application (Genzyme Corporation)

View source ↗

Summary

FDA approved a supplemental application for Cablivi (caplacizumab) submitted by Genzyme, resulting in changes to the product labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acquired Thrombotic Thrombocytopenic Purpura

Drugs mentioned

• CABLIVI (CAPLACIZUMAB)

Snippet

SUPPL AP for CABLIVI (CAPLACIZUMAB)